ZymeTx, Inc. - ZMTX new biotech company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ZymeTx, Inc. - ZMTX new biotech company

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tyndall who wrote (21)	12/10/1997 11:38:00 PM
From: O. H. Rundell	Read Replies (1) of 88

Excerpts Millennium Financial Group Research Report -- ZymeTx, Inc. by Anthony Mannara Price (12/1/97) : $9.25 Common Shares: : 8 million Fully Diluted Float : 55.7% Market Cap. : $74 million Major Shareholders : Management Ownership 7.70% Exchange Traded : NASDAQ Symbol : ZMTX *Recommendation : BUY* Highlights: * There are over 155 million significant respiratory viral infections per year in the U.S. alone which represent the #1 reason for visiting a doctor. Influenza is the greatest contributor of upper respiratory illness which represents the 5th leaning cause of death. It is estimated that there are at least 70 million cases of influenza per year in the U.S. alone. * The Journal of the AMA reports that 21% of all antibiotics prescribed to adults were for the treatment of colds, bronchitis, and unspecified upper respiratory infections, even though more than 90% of such infections are caused by viruses which are impervious to antibiotics. Besides the cost of misuse of antibiotics, their administration generates rapid growth of drug-resistant bacteria which, in turn, calls for the development of stronger and more expensive antibiotics. The utilization by managed care facilities of ZymeTx diagnostics for influenza could dramatically reduce the cost of this inefficiency in the healthcare system which is estimated to exceed $30 billion. * Besides savings derived from proper prescription of antibiotics, additional cost benefits to the U.S. healthcare system will result from: Fewer repeat office visits because of accurate diagnosis. The simplicity of the diagnostic procedure requires only 60 seconds of hands on time and one hour of incubation, and can be performed by a qualified technician under doctor supervision -- thus permitting more efficient use of the physician's time. * A pharmaco-economic model forecasts that use of ZstatFlu can generate a 13% savings to managed care companies. Year EPS P/E P/BV 1997 N/A N/A 54.1 1998 0.46 20.6 2.8 1999 2.18 4.2 1.7 2000 4.14 2.2 1.0 More to come....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next